Should we lower lipids in nonalcoholic fatty liver disease?

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 1, 2014, Pages 152-155

  Farrell, Geoffrey ^a  

^a The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ATHEROMATOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; CHRONIC KIDNEY DISEASE; DIABETES CONTROL; DRUG MEGADOSE; DRUG POTENTIATION; DYSLIPIDEMIA; ENZYME INDUCTION; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOTOXICITY; LIVER INJURY; MYOPATHY; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; UPREGULATION; VASCULAR ENDOTHELIUM; WEIGHT REDUCTION; FATTY LIVER;

ANTICHOLESTEREMIC AGENTS; FATTY LIVER; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84890216105     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.07.041     Document Type: Review

References (29)

1. Larter C.Z., Chitturi S., Farrell G.C. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010, 25:672-690.
2. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012, 142:711-725.
3. Farrell G.C., Wong V.W., Chitturi S. NAFLD in Asia-as common and important as in the West. Nat Rev Gastro Hep 2013, 10:307-318.
4. Loomba R., Abraham M., Unalp A., et al. Association between diabetes, family history of diabetes and risk of non-alcoholic steatohepatitis and fibrosis. Hepatology 2012, 56:943-951.
5. Corey K.E., Lai M., Gelrud L.G., et al. Non-high-density lipoprotein cholesterol as a biomarker for non-alcoholic steatohepatitis. Clin Gastroenterol Hepatol 2012, 10:651-656.
6. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
7. Musso G., Cassader M., Rosina F., et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD). Diabetologia 2012, 55:885-904.
8. Athyros V.G., Tziomalos K., Gossios T.D., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Artorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010, 376:1916-1922.
9. Cohen D.E., Anania F.A., Chalasani N. National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006, 97:77C-81C.
10. Neuschwander-Tetri B.A. Hepatic lipotoxicity and pathogenesis of nonalcoholic steato-hepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52:774-788.
11. Malhi H., Gores G. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28:360-369.
12. Puri P., Baillie R.A., Wiest M.M., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46:1081-1090.
13. Caballero F., Fernández A., De Lacy A.M., et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. JHepatol 2009, 50:789-796.
14. Wouters K., van Gorp P.J., Bieghs V., et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008, 48:474-486.
15. Farrell G.C., van Rooyen D. Liver cholesterol: is it playing possum in NASH?. Am J Physiol Gastrointest Liver Physiol 2012, 303:G9-G11.
16. Arteel G.E. Beyond reasonable doubt: who is the culprit in lipotoxicity in NAFLD/NASH?. Hepatology 2012, 55:2030-2032.
17. Van Rooyen D.M., Larter C.Z., Haigh W.G., et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011, 141:1393-1403.
18. Min H.K., Kapoor A., Fuchs M., et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012, 15:665-674.
19. Van Rooyen D.M., Gan L.T., Yeh M.M., et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice. J Hepatol 2013, 59:144-152.
20. Matsuzawa N., Takamura T., Kurita S., et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007, 46:1392-1403.
21. Ogawa T., Fujii H., Yoshizato K., et al. A human-type non-alcoholic steatohepatitis model with advanced fibrosis in rabbits. Am J Pathol 2010, 177:153-165.
22. Charlton M., Krishnan A., Viker K., et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011, 301:G825-G834.
23. Neuschwander-Tetri B.A., Ford D.A., Acharya S., et al. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids 2012, 47:941-950.
24. Kohli R., Kirby M., Xanthakos S.A., et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma co-enzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010, 52:934-944.
25. Hawas B.E., O'Neill K.A., Yao X., et al. In vivo responsiveness to ezetimibe correlates with Niemann-Pick C1-like-1 (NPC1L1) binding affinity: comparison of multiple species NPC1L1 orthologs. Mol Pharm 2007, 71:19-29.
26. Musso G., Molinaro F., Paschetta E., et al. Lipid modifiers and NASH: statins, ezetimibe, fibrates, and other agents. Non-alcoholic fatty liver disease: a practical guide 2013, 293-307. Wiley-Blackwell, Oxford. G.C. Farrell, A.J. McCullough, C.P. Day (Eds.).
27. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
28. Park H., Shima T., Yamaguchi K., et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011, 46:101-107.
29. Mudaliar S., Henry R.R., Sanyal A.J., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and non-alcoholic fatty liver disease. Gastroenterology 2013, 145:574-582.